Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
0.1-0.3μg/ml |
10μg/ml |
10μg/ml |
Not tested in other applications.
Calculated MW
Predict Reactivity
Rat, Bovine, Dog(>80% identity)
Form
Liquid
Buffer
Tris, 0.5% BSA
Preservative
0.02% sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Peptide with sequence C-SVDSRFRGKGIAK, from the internal region of the protein sequence according to NP_001001985.3.
Purification
Ammonium sulphate precipitation followed by peptide affinity purification
From serum
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
N-acetyltransferase 8 like , CML3 , NACED , NAT8-LIKE
Cellular Localization
Cytoplasm , Membrane
Background
This gene encodes a single-pass membrane protein, which contains a conserved sequence of the GCN5 or NAT superfamily of N-acetyltransferases and is a member of the N-acyltransferase (NAT) superfamily. This protein is a neuron-specific protein and is the N-acetylaspartate (NAA) biosynthetic enzyme, catalyzing the NAA synthesis from L-aspartate and acetyl-CoA. NAA is a major storage and transport form of acetyl coenzyme A specific to the nervous system. The gene mutation results in primary NAA deficiency (hypoacetylaspartia). [provided by RefSeq, Dec 2010]
Database